Feb. 11, 2026
— Jeff Ward, Lehigh Valley News Briefs
OraSure Technologies will report fourth-quarter earnings on Feb. 25.
Investors in the Bethlehem-based maker of diagnostic kits will be curious to see the numbers, but Wall Street shows little interest in the company.
OraSure has been reporting dreary results for a long time. Revenue has been falling since the COVID-19 pandemic. OraSure consistently loses money and destroys long-term shareholders’ wealth.
Wall Street isn’t spending much time on OraSure. Zacks Investment Research, which compiles revenue and earnings estimates, features just one analyst estimate for OraSure’s fourth-quarter results. Sales are projected at $26.3 million, with only the one estimate, and the loss per share is expected to be 17 cents. So there are no consensus estimates so far, just one call.
Shares (NASDAQ:OSUR) were trading at $2.74 at 10:43 a.m. Wednesday. That gives the company a market capitalization (share price times number of shares outstanding) of $200.8 million. That “market cap” explains the meager analyst coverage.
The maker of the OraQuick home HIV test and InteliSwab COVID test has been muddling along since the pandemic ended and the flow of federal dollars fell. Federal money built OraSure’s “Factory of the Future” in Bethlehem Township, but what is the future?
OraSure has acknowledged the threat from government cuts to healthcare spending. Perhaps we will hear more about that on the conference call.
The company is controlled by institutional investors, who have bigger things to worry about but how long will their patience last?
Chief Executive Carrie Eglinton Manner took over in June 2022. She has cut jobs, cut costs and made a couple small acquisitions, but the stock has done nothing. It traded at $3.85 the day before she took over.
I hope the company doesn’t indulge in more jargon during its conference call after the earnings come out. That helps nobody.
The 52-week high for the shares is $4.22, and the low is $2.08.
Here’s a link to OraSure’s press release, and below is a cut-and-paste version:
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
February 9, 2026 at 4:15 PM EST
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.
A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com
Lehigh Valley News Briefs 